# SkinVision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/skinvision

- Industry: Healthcare IT
- Headquarters: Amsterdam, Netherlands
- Website: www.skinvision.com
- Total disclosed funding: $11M
- Latest round: Series B (Jul 30, 2018)
- Investors on record: 2

## About

SkinVision BV is a health technology company specializing in skin cancer detection through an innovative mobile application that utilizes artificial intelligence and expert dermatological insights to enhance skin health monitoring.Founded in 2011, SkinVision BV is headquartered in Amsterdam, Netherlands, and focuses on skin cancer detection through its mobile app. The company has raised a total of USD 7.60 mn in funding, with the latest round being a Series B on July 7, 2020, supported by investors including LEO Pharma A/S and Personal Health Solutions Capital. The company has completed five deals to date.SkinVision offers a mobile application specifically designed for skin cancer detection, leveraging advanced artificial intelligence technology and the expertise of dermatology professionals. The app enables users to conduct self-examinations of their skin by allowing them to take photographs of moles or skin spots, which are then analyzed by the app's algorithm. This service aims to resolve critical user concerns about skin health by providing insights into potential skin cancer risks and suggesting actions for follow-up. The app is particularly beneficial for individuals who spend significant time outdoors, as it emphasizes the importance of regular skin checks due to the high correlation between UV radiation exposure and skin cancer. SkinVision is accessible in various geographical markets, including the Netherlands, Belgium, and the United Kingdom, catering to a diverse customer base that includes over 3 million users globally.The revenue model for SkinVision is primarily based on subscription services, where users pay for access to the app's features, which include skin health assessment and personalized recommendations. Users can choose from various pricing plans that may include monthly or yearly subscription options, granting them the ability to perform multiple skin checks and access expert advice. Through direct-to-consumer transactions, the app facilitates a streamlined experience for users, allowing them to manage their skin health effectively. The company has positioned its offerings as a vital tool for proactive skin health management, emphasizing the app's clinical validation and accuracy, thus attracting a substantial and loyal customer base.In July 2020, SkinVision BV raised USD 7.60 mn in venture funding, which will support the development of new features within the app and enhance its machine learning capabilities. The company aims to expand its market presence by targeting additional regions across Europe and beyond, focusing on countries with high incidences of skin cancer. These initiatives underscore SkinVision's commitment to improving skin health surveillance and increasing user engagement.

## Funding rounds

- Series B, Jul 30, 2018, $7.6M — LEO Pharma A/S, Personal Health Solutions Capital
- Series A, Aug 23, 2015, $3.4M — LEO Pharma A/S, Personal Health Solutions Capital

## Investors

- LEO Pharma A/S — Series A, Series B
- Personal Health Solutions Capital (https://capitalatlas.ai/funds/personal-health-solutions-capital) — Series A, Series B